Literature DB >> 9338787

Lipopolysaccharide-binding protein is required to combat a murine gram-negative bacterial infection.

R S Jack1, X Fan, M Bernheiden, G Rune, M Ehlers, A Weber, G Kirsch, R Mentel, B Fürll, M Freudenberg, G Schmitz, F Stelter, C Schütt.   

Abstract

An invading pathogen must be held in check by the innate immune system until a specific immune response can be mounted. In the case of Gram-negative bacteria, the principal stimulator of the innate immune system is lipopolysaccharide (LPS), a component of the bacterial outer membrane. In vitro, LPS is bound by lipopolysaccharide-binding protein (LBP) and transferred to CD14--the LPS receptor on the macrophage surface--or to high-density lipoprotein (HDL) particles. Transfer to CD14 triggers an inflammatory response which is crucial for keeping an infection under control. Here we investigate how LBP functions in vivo by using LBP-deficient mice. Surprisingly, we find that LBP is not required in vivo for the clearance of LPS from the circulation, but is essential for the rapid induction of an inflammatory response by small amounts of LPS or Gram-negative bacteria and for survival of an intraperitoneal Salmonella infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9338787     DOI: 10.1038/39622

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  66 in total

Review 1.  Bloodstream infections: epidemiology, pathophysiology and therapeutic perspectives.

Authors:  R Salomão; O Rigato; A C Pignatari; M A Freudenberg; C Galanos
Journal:  Infection       Date:  1999 Jan-Feb       Impact factor: 3.553

Review 2.  The biology of endotoxin.

Authors:  H Heine; E T Rietschel; A J Ulmer
Journal:  Mol Biotechnol       Date:  2001-11       Impact factor: 2.695

3.  Dual role of lipopolysaccharide (LPS)-binding protein in neutralization of LPS and enhancement of LPS-induced activation of mononuclear cells.

Authors:  T Gutsmann; M Müller; S F Carroll; R C MacKenzie; A Wiese; U Seydel
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

Review 4.  TLR4 polymorphisms and disease susceptibility.

Authors:  Mamoona Noreen; Muhammad Ali A Shah; Sheeba Murad Mall; Shazia Choudhary; Tahir Hussain; Iltaf Ahmed; Syed Fazal Jalil; Muhammad Imran Raza
Journal:  Inflamm Res       Date:  2012-01-26       Impact factor: 4.575

Review 5.  Accessory molecules for Toll-like receptors and their function.

Authors:  Clarissa C Lee; Ana M Avalos; Hidde L Ploegh
Journal:  Nat Rev Immunol       Date:  2012-02-03       Impact factor: 53.106

6.  Lipopolysaccharide binding protein is down-regulated during acute liver failure.

Authors:  Grace L Su; Robert J Fontana; Kartik Jinjuvadia; Jill Bayliss; Stewart C Wang
Journal:  Dig Dis Sci       Date:  2012-01-26       Impact factor: 3.199

7.  LPS-binding protein enables intestinal epithelial restitution despite LPS exposure.

Authors:  Juli M Richter; Brandon L Schanbacher; Hong Huang; Jianjing Xue; John A Bauer; Peter J Giannone
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-05       Impact factor: 2.839

8.  Acute-phase concentrations of lipopolysaccharide (LPS)-binding protein inhibit innate immune cell activation by different LPS chemotypes via different mechanisms.

Authors:  Lutz Hamann; Christian Alexander; Cordula Stamme; Ulrich Zähringer; Ralf R Schumann
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

Review 9.  Modulating LPS signal transduction at the LPS receptor complex with synthetic Lipid A analogues.

Authors:  Aileen F B White; Alexei V Demchenko
Journal:  Adv Carbohydr Chem Biochem       Date:  2014       Impact factor: 12.200

10.  Burn-induced heart failure: lipopolysaccharide binding protein improves burn and endotoxin-induced cardiac contractility deficits.

Authors:  Andreas D Niederbichler; Laszlo M Hoesel; Kyros Ipaktchi; Leovigildo Olivarez; Martin Erdmann; Peter M Vogt; Grace L Su; Saman Arbabi; Margaret V Westfall; Stewart C Wang; Mark R Hemmila
Journal:  J Surg Res       Date:  2009-12-06       Impact factor: 2.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.